WEKO3
アイテム
{"_buckets": {"deposit": "59c14367-06fa-4188-b58c-0ba3ec69c8ce"}, "_deposit": {"created_by": 1, "id": "46736", "owners": [1], "pid": {"revision_id": 0, "type": "depid", "value": "46736"}, "status": "published"}, "_oai": {"id": "oai:repo.qst.go.jp:00046736", "sets": ["1"]}, "author_link": ["466053", "466056", "466061", "466063", "466057", "466060", "466055", "466065", "466064", "466054", "466059", "466062", "466058"], "item_8_biblio_info_7": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2013-12", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "8", "bibliographicPageEnd": "878", "bibliographicPageStart": "872", "bibliographicVolumeNumber": "39", "bibliographic_titles": [{"bibliographic_title": "Cancer Treatment Reviews"}]}]}, "item_8_description_5": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "The prognosis of high-risk prostate cancer is poor with a high mortality rate. The Radiation Therapy Oncology Group (RTOG) has performed dose-escalation studies of external beam radiation therapy (EBRT) and has developed high-precision radiation therapy (RT) methods such as intensity-modulated RT, carbon ion therapy, and proton beam therapy. High-dose rate brachytherapy (HDR-BT) is also studied as an option for high-risk prostate cancer treatment. Past clinical trials have suggested that the local control rate of high-risk prostate cancer improves with total EBRT dose, even for doses \u003e70 Gy. Several randomized controlled trials, including RTOG 94-06, have shown significantly better prognoses with higher doses (\u003e75 Gy) than with lower doses (\u003c70 Gy). A proton beam therapy trial (PROG 95\u0026#8211;09) also showed similar results. A phase II clinical trial (National Institute for Radiological Sciences, Japan; trial 9904) showed that carbon ion therapy resulted in very good biochemical recurrence-free survival rates among high-risk prostate cancer patients, demonstrating particle therapy to be a valid treatment option. RTOG 86-10 showed that short-term neo-adjuvant hormonal therapy (HT) was inadequate for high-risk prostate cancer but effective for intermediate-risk prostate cancer, whereas RTOG 92-02 and the European Organisation for Research and Treatment of Cancer (EORTC) 22863 showed significant improvements in the prognosis of high-risk groups receiving long-term (\u003e2 years) HT combined with definitive RT. Further studies are warranted to elucidate optimal irradiation doses, HT treatment durations, and combination therapy schedules.", "subitem_description_type": "Abstract"}]}, "item_8_relation_14": {"attribute_name": "DOI", "attribute_value_mlt": [{"subitem_relation_type_id": {"subitem_relation_type_id_text": "10.1016/j.ctrv.2013.04.003", "subitem_relation_type_select": "DOI"}}]}, "item_8_source_id_9": {"attribute_name": "ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "0305-7372", "subitem_source_identifier_type": "ISSN"}]}, "item_access_right": {"attribute_name": "アクセス権", "attribute_value_mlt": [{"subitem_access_right": "metadata only access", "subitem_access_right_uri": "http://purl.org/coar/access_right/c_14cb"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "Nomiya, Takuma"}], "nameIdentifiers": [{"nameIdentifier": "466053", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Tsuji, Hiroshi"}], "nameIdentifiers": [{"nameIdentifier": "466054", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Toyama, Shingo"}], "nameIdentifiers": [{"nameIdentifier": "466055", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Maruyama, Katsuya"}], "nameIdentifiers": [{"nameIdentifier": "466056", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Nemoto, Kenji"}], "nameIdentifiers": [{"nameIdentifier": "466057", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Tsujii, Hirohiko"}], "nameIdentifiers": [{"nameIdentifier": "466058", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Kamada, Tadashi"}], "nameIdentifiers": [{"nameIdentifier": "466059", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "野宮 琢磨", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "466060", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "辻 比呂志", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "466061", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "戸山 真吾", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "466062", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "丸山 克也", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "466063", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "辻井 博彦", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "466064", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "鎌田 正", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "466065", "nameIdentifierScheme": "WEKO"}]}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "journal article", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "Management of high-risk prostate cancer: Radiation therapy and hormonal therapy", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "Management of high-risk prostate cancer: Radiation therapy and hormonal therapy"}]}, "item_type_id": "8", "owner": "1", "path": ["1"], "permalink_uri": "https://repo.qst.go.jp/records/46736", "pubdate": {"attribute_name": "公開日", "attribute_value": "2014-03-05"}, "publish_date": "2014-03-05", "publish_status": "0", "recid": "46736", "relation": {}, "relation_version_is_last": true, "title": ["Management of high-risk prostate cancer: Radiation therapy and hormonal therapy"], "weko_shared_id": -1}
Management of high-risk prostate cancer: Radiation therapy and hormonal therapy
https://repo.qst.go.jp/records/46736
https://repo.qst.go.jp/records/46736a6b9d73d-d33b-4705-8546-b0957150e43f
Item type | 学術雑誌論文 / Journal Article(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2014-03-05 | |||||
タイトル | ||||||
タイトル | Management of high-risk prostate cancer: Radiation therapy and hormonal therapy | |||||
言語 | ||||||
言語 | eng | |||||
資源タイプ | ||||||
資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
資源タイプ | journal article | |||||
アクセス権 | ||||||
アクセス権 | metadata only access | |||||
アクセス権URI | http://purl.org/coar/access_right/c_14cb | |||||
著者 |
Nomiya, Takuma
× Nomiya, Takuma× Tsuji, Hiroshi× Toyama, Shingo× Maruyama, Katsuya× Nemoto, Kenji× Tsujii, Hirohiko× Kamada, Tadashi× 野宮 琢磨× 辻 比呂志× 戸山 真吾× 丸山 克也× 辻井 博彦× 鎌田 正 |
|||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | The prognosis of high-risk prostate cancer is poor with a high mortality rate. The Radiation Therapy Oncology Group (RTOG) has performed dose-escalation studies of external beam radiation therapy (EBRT) and has developed high-precision radiation therapy (RT) methods such as intensity-modulated RT, carbon ion therapy, and proton beam therapy. High-dose rate brachytherapy (HDR-BT) is also studied as an option for high-risk prostate cancer treatment. Past clinical trials have suggested that the local control rate of high-risk prostate cancer improves with total EBRT dose, even for doses >70 Gy. Several randomized controlled trials, including RTOG 94-06, have shown significantly better prognoses with higher doses (>75 Gy) than with lower doses (<70 Gy). A proton beam therapy trial (PROG 95–09) also showed similar results. A phase II clinical trial (National Institute for Radiological Sciences, Japan; trial 9904) showed that carbon ion therapy resulted in very good biochemical recurrence-free survival rates among high-risk prostate cancer patients, demonstrating particle therapy to be a valid treatment option. RTOG 86-10 showed that short-term neo-adjuvant hormonal therapy (HT) was inadequate for high-risk prostate cancer but effective for intermediate-risk prostate cancer, whereas RTOG 92-02 and the European Organisation for Research and Treatment of Cancer (EORTC) 22863 showed significant improvements in the prognosis of high-risk groups receiving long-term (>2 years) HT combined with definitive RT. Further studies are warranted to elucidate optimal irradiation doses, HT treatment durations, and combination therapy schedules. | |||||
書誌情報 |
Cancer Treatment Reviews 巻 39, 号 8, p. 872-878, 発行日 2013-12 |
|||||
ISSN | ||||||
収録物識別子タイプ | ISSN | |||||
収録物識別子 | 0305-7372 | |||||
DOI | ||||||
識別子タイプ | DOI | |||||
関連識別子 | 10.1016/j.ctrv.2013.04.003 |